The Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) are alerting consumers and health care providers to five reports of Guillain Barre Syndrome (GBS) following administration of Meningococcal Conjugate Vaccine A, C, Y, and W135 (trade name Menactra), manufactured by Sanofi Pasteur. It is not known yet whether these cases were caused by the vaccine or are coincidental. FDA and CDC are sharing this information with the public now and actively investigating the situation because of its potentially serious nature
Guillain Barre Syndrome (GBS) is a serious neurological disorder that can occur, often in healthy individuals, either spontaneously or after certain infections. GBS typically causes increasing weakness in the legs and arms that can be severe and require hospitalization.
Meningococcal infection, which Menactra prevents, is a major cause of bacterial meningitis, affecting approximately 1 in 100,000 people annually. The infection can be life threatening: 10-14 percent of cases are fatal and 11-19 percent of survivors may have permanent disability.
The pediatricians and nurse practitioners at the Pediatric Group are dedicated to providing the highest quality and most comprehensive care to your child to help you ensure their health and well-being, now and as they continue growing. Developmental testing is an important component of a well child exam. Developmental testing is designed to further the optimal development of children from birth to six years of age through guidance and identification of those who may require additional evaluation. The pediatrician's office is ideal for developmental and behavioral screening. Routine physical examinations are the most important way to monitor and assess your child’s development
